Dachaigh › Aillse Sgamhain Neo-chealla-beag › Texas › Dallas
Sgrùdaidhean clionaigeach Aillse Sgamhain Neo-chealla-beag ann an Dallas, TX
Tha 52 sgrùdaidhean airson Aillse Sgamhain Neo-chealla-beag a’ lorg phàirtichean aig làraichean ann agus timcheall air Dallas (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
A’ fastadhÌre 2
- Texas Oncology - Dallas - Worth Street /ID# 278947, Dallas
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
A’ fastadhÌre 3
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
A’ fastadhÌre 1/2
- UT Southwest Simmons Cancer Center, Dallas
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
A’ fastadhÌre 3
- Texas Oncology - DFW ( Site 8103), Dallas
- UT Southwestern Medical Center ( Site 0190), Dallas
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
A’ fastadhÌre 1
- Exelixis Clinical Site #89, Dallas
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
A’ fastadhÌre 1
- SCRI at Mary Crowley, Dallas
- University of Texas Southwestern Medical Center, Dallas
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
A’ fastadhÌre 3
- Texas Oncology Dallas, Dallas
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
A’ fastadhÌre 3
- Texas Oncology - DFW, Dallas
- Texas Oncology - DFW, Dallas
- Texas Oncology - DFW, Dallas
- agus 2 a bharrachd
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A’ fastadhÌre 3
- Texas Oncology - DFW, Dallas
- Texas Oncology - DFW, Dallas
- Texas Oncology - DFW, Dallas
- agus 2 a bharrachd
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A’ fastadhÌre 2
- Parkland Health and Hospital System, Dallas
- Texas Oncology DFW, Dallas
- UT Southwestern Medical Center, Dallas
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
A’ fastadhÌre 1
- Research Site, Dallas
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
A’ fastadhÌre 1/2
- Baylor, Scott and White Research Institute, Dallas
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
A’ fastadhÌre 1
- UT Southwestern Medical Center at Dallas, Dallas
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
A’ fastadhÌre 3
- Texas Oncology Sammons Cancer Center, Dallas
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
A’ fastadhÌre 3
- Clinical Study Site, Dallas
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
A’ fastadhÌre 1
- NEXT - Dallas, Dallas
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
A’ fastadhÌre 2/3
- Texas Oncology - Dallas Fort Worth (DFW) - Baylor Charles A. Sammons Cancer Center, Dallas
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
A’ fastadhSgrùdadh amharc
- UT Southwestern Medical Center, Dallas
A Study of KK2269 in Adult Participants With Solid Tumors
A’ fastadhÌre 1
- The University of Texas Southwestern Medical Center, Dallas
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
A’ fastadhÌre 1/2
- Mary Crowley Cancer Research, Dallas
A Phase 1/1b Study of IAM1363 in HER2 Cancers
A’ fastadhÌre 1
- Mary Crowley Cancer Research, Dallas
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
A’ fastadhÌre 3
- The University of Texas Southwestern Medical Center at Dallas, Dallas
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
A’ fastadhÌre 1
- Ut Southwestern, Dallas
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
A’ fastadhÌre 3
- Texas Oncology, Dallas
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
A’ fastadhÌre 2
- Baylor Charles A. Sammons Cancer Center, Dallas
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
A’ fastadhÌre 1/2
- Texas Oncology - DFW, Dallas
A Study of DM005 in Patients With Advanced Solid Tumors
A’ fastadhÌre 1/2
- Sarah Cannon Research Institute at Mary Crowley, Dallas
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
A’ fastadhÌre 1/2
- Mary Crowley Cancer Research, Dallas
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
A’ fastadhÌre 1
- University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
- UT Southwestern Medical Center - Redbird, Dallas
- Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital, Dallas
- agus 2 a bharrachd
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
A’ fastadhÌre 2
- Texas Oncology - DFW, Dallas
Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung
A’ fastadhÌre 1 tràth
- University of Texas Southwestern Medical Center, Dallas
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
A’ fastadhÌre 3
- Old Parkland Hospital Hematology Oncology Clinic, Dallas
- UT Southwestern Medical Center, Dallas
Study of XB010 in Subjects With Solid Tumors
A’ fastadhÌre 1
- Baylor University Medical Center, Dallas
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
A’ fastadhÌre 1
- NEXT Texas LLC - Dallas, Dallas
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
A’ fastadhÌre 1
- UT Southwestern Simmons Cancer Center, Dallas
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
A’ fastadhÌre 1
- University of Texas Southwestern Medical Center /ID# 251974, Dallas
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
A’ fastadhÌre 1
- Sarah Cannon Research Institute at Mary Crowley, Dallas
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
A’ fastadhÌre 1
- Sarah Cannon Research Institute at Mary Crowley, Dallas
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
A’ fastadhÌre 1/2
- UT Southwestern Medical Center, Dallas
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
A’ fastadhÌre 1/2
- Mary Crowley Cancer Research, Dallas
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
A’ fastadhÌre 2
- UT Southwestern Medical Center, Dallas
Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
A’ fastadhÌre 2
- University of Texas Southwestern Medical Center, Dallas
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
A’ fastadhÌre 3
- University of Texas Southwestern Medical Center, Dallas
A Study of VET3-TGI in Patients With Solid Tumors
A’ fastadhÌre 1
- Mary Crowley Cancer Research, Dallas
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
A’ fastadhÌre 1
- NEXT Dallas, Dallas
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
A’ fastadhÌre 1/2
- Research Site, Dallas
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
A’ fastadhÌre 1/2
- NEXT Oncology - Dallas, Dallas
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
A’ fastadhÌre 1/2
- NEXT Oncology Dallas, Dallas
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
A’ fastadhÌre 1
- Dren Investigational Site, Dallas
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
A’ fastadhÌre 1/2
- Research Site 120, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
A’ fastadhSgrùdadh amharc
- Massive Bio SYNERGY-AI site, Dallas
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- Baylor Scott and White Research Institute, Dallas
Sgrùdaidhean Aillse Sgamhain Neo-chealla-beag ann am bailtean eile
- Houston, TX145 sgrùdaidhean
- New York City, NY121 sgrùdaidhean
- Arlington, VA104 sgrùdaidhean
- Nashville, TN97 sgrùdaidhean
- Boston, MA90 sgrùdaidhean
- Los Angeles, CA87 sgrùdaidhean
- St. Louis, MO73 sgrùdaidhean
- Chicago, IL61 sgrùdaidhean
- Baltimore, MD60 sgrùdaidhean
- San Antonio, TX59 sgrùdaidhean
- Columbus, OH57 sgrùdaidhean
- Washington, DC55 sgrùdaidhean
Sgrùdaidhean eile ann an Dallas
- Aillse a' bhroilleach55 sgrùdaidhean
- Ailse metastatach42 sgrùdaidhean
- Fàilligeadh a' Chridhe42 sgrùdaidhean
- Aillse (gach seòrsa)37 sgrùdaidhean
- Aillse Prostata36 sgrùdaidhean
- Aillse colorectal33 sgrùdaidhean
- Obesity30 sgrùdaidhean
- Cancer Ovarian28 sgrùdaidhean
- Ailseachadh nan Sgamhan27 sgrùdaidhean
- Aillse sa bhlaire27 sgrùdaidhean
- Ailse Endometrial24 sgrùdaidhean
- Aillse nan dubhagan (Carcinoma cealla renach)23 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.